MAJI (Exousia Pro) Notes Receivable: $0.00 Mil (As of Jan. 2021)


What is Exousia Pro Notes Receivable?

Exousia Pro MAJI -1.92% Notes Receivable is $0.00 Mil as of Jan. 2021.

Exousia Pro's Notes Receivable for the quarter that ended in Jan. 2021 was $0.00 Mil.

Exousia Pro Notes Receivable Historical Data

* Premium members only.

The historical data trend for Exousia Pro's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exousia Pro Notes Receivable Chart

Exousia Pro Annual Data
Trend Apr11 Apr12 Apr18 Apr19
Notes Receivable
0.00 0.00 0.00 0.00

Exousia Pro Quarterly Data
Oct11 Jan12 Apr12 Jul12 Oct12 Jan13 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Exousia Pro Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Exousia Pro (MAJI) has a Notes Receivable of $0.00 Mil as of Jan. 2021. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Exousia Pro and its competitors.
Is Exousia Pro's Notes Receivable too high?
Exousia Pro's current Notes Receivable is $0.00 Mil.
How does Exousia Pro's Notes Receivable compare to HCCH and GRNV?
Exousia Pro's Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Exousia Pro and its competitors. Exousia Pro's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exousia Pro stock overvalued right now?
Exousia Pro (MAJI) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Exousia Pro (MAJI), the current Notes Receivable is $0.00 Mil as of Jan. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Exousia Pro Business Description

Address 7901 4th Street North, No. 23494, St. Petersburg, FL, USA, 33702
Exousia Pro Inc is a exosome-based biotechnology, develops and manufactures mammalian and plant-based exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company is developing new ways to exploit the therapeutic potential of exosomes, initially focused in the field of oncology. The platform technology of the company also helps treating a broad spectrum of viral infections.